Abstract: The present invention provides compounds of Formula I: (I) along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.
Type:
Grant
Filed:
July 23, 2009
Date of Patent:
May 14, 2013
Assignee:
Duke University
Inventors:
Katherine J. Franz, Katie L. Ciesienski
Abstract: Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses.
Type:
Grant
Filed:
February 29, 2012
Date of Patent:
April 30, 2013
Assignee:
Besins Healthcare Luxembourg SARL
Inventors:
John Brennan, Earl E. Sands, Rex Horton, Zurab Bebia
Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.
Abstract: The present invention relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering to a subject an amount of an A3RM, the amount being effective to modulate A3AR activity. The A3RM according to the invention are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. The invention also provides some of such novel 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.
Type:
Grant
Filed:
July 28, 2008
Date of Patent:
April 16, 2013
Assignees:
The United States of America, represented by the Secretary, Dept. of Health and Human Services, Universiteit Leiden
Inventors:
Aniko Goblyos, Johannes Brussee, Adriaan P. Ijzerman, Zhan-Guo Gao, Kenneth Jacobson
Abstract: The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof.
Abstract: The present invention embraces compounds selected for interacting with the T-pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase.
Abstract: The present invention relates to specific oxalic acid derivatives and to corresponding mixtures and to uses thereof as physiological cooling active ingredients.
Type:
Grant
Filed:
August 18, 2008
Date of Patent:
January 1, 2013
Assignee:
Symrise AG
Inventors:
Horst Surburg, Jan Looft, Heiko Oertling, Tobias Vössing
Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2 -isopropylpyrazolo[1,5-a]pyridine).
Type:
Grant
Filed:
February 22, 2012
Date of Patent:
December 25, 2012
Assignee:
Medicinova, Inc.
Inventors:
Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.
Abstract: The use of nanoparticles of inorganic materials (e.g., synthetic smectite clays) in ophthalmic and otic pharmaceutical compositions is described. The nanoparticles are utilized as biologically inert carriers or depots for ophthalmic and otic drugs. The nanoparticles may also be utilized to modify the rheological properties of the compositions, so as to enhance the viscosity or flow characteristics of the compositions and/or increase the retention time of the compositions in the eye or ear.
Type:
Grant
Filed:
July 19, 2011
Date of Patent:
September 4, 2012
Assignee:
Novartis AG
Inventors:
Howard Allen Ketelson, David L. Meadows
Abstract: A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. In some embodiments, the S100 protein is S100P. In some embodiments, the S100 protein is S100P. In addition, the present invention provides a method of treating a cancer comprising administering to a mammal a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. Additional methods are also provided.
Abstract: A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH2)m2-, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R6, R7 and R8 independently represent a lower alkyl group or the like].
Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Type:
Grant
Filed:
July 8, 2008
Date of Patent:
March 20, 2012
Assignee:
MediciNova, Inc.
Inventors:
Michael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
Type:
Grant
Filed:
November 10, 2006
Date of Patent:
December 13, 2011
Assignee:
Eli Lilly and Company
Inventors:
Mark Donald Chappell, Scott Eugene Conner, Philip Arthur Hipskind, Jason Eric Lamar, Guoxin Zhu
Abstract: This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
December 13, 2011
Assignee:
The Board of Trustees of the University of Illinois
Abstract: There is provided a compound of Formula (III) wherein R1 is a selected from an alkyloxyalkyl group, a nitrile group, alkylaryl group, alkenylaryl group, alkylheteroaryl group, alkenylheteroaryl group, ?N—O—alkyl or ?N—O—H group, branched alkenyl, alkyl-alcohol group, amide or alkylamide or —CHO so that R1 together with R3 provide the enol tautomer or R1 together with R3 form a pyrazole, wherein (a) R4 is ?N—O-alkyl or ?N—O—H group, (b) the pyrazole is substituted with one of alkyl-OH group, alkyl ester group, alkyloxyalkyl group, branched alkyl group, and an amide and/or (c) the 2-position is substituted with a group selected from —OH and —O-hydrocarbyl or a heteroaryl ring; R2 is selected from —OH and a sulphamate group; and R3 is selected from —OH or ?O; wherein the ring system may be further substituted with one or more hydroxyl, alkyl, alkoxy, alkinyl or halo substituents.
Type:
Grant
Filed:
September 23, 2005
Date of Patent:
August 23, 2011
Assignee:
Sterix Limited
Inventors:
Nigel Vicker, Harshani Rithma Ruchiranani Lawrence, Gillian Margaret Allan, Christian Bubert, Delphine Sophie Marion Fischer, Atul Purohit, Michael John Reed, Barry Victor Lloyd Potter
Abstract: The present invention provides an oral grain preparation comprising an agent swellable in the mouth as an active component, wherein the preparation has an inner coating layer of a water-soluble cellulose polymer and an outer coating layer of an ethylcellulose on a plain grain having a diameter of 3 to 4 mm. The agent of the present invention is free from sliminess peculiar to cellulose and adherence of each grains in the mouth at taking, and has excellent feeling for taking without an unpleasant feeling such as caused by a large tablet.